MARKET

ADRO

ADRO

Aduro Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.655
-0.105
-3.80%
Opening 09:46 09/21 EDT
OPEN
2.750
PREV CLOSE
2.760
HIGH
2.750
LOW
2.610
VOLUME
20.17K
TURNOVER
--
52 WEEK HIGH
4.040
52 WEEK LOW
0.9011
MARKET CAP
215.50M
P/E (TTM)
-3.3138
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ONE, REDU, JKHY and KFY among after-hours movers
Gainers: [[ONE]] +17.9%. [[ADRO]] +8.4%. [[CRS]] +4.5%. [[SCHN]] +4.0%. [[REDU]] +3.5%.Losers: [[SABR]] -10.5%. [[JKHY]] -7.5%. [[KFY]] -4.7%. [[EBON]] -3.5%. [[A]] -3.2%.
Seekingalpha · 08/18 21:30
SHIP, FORD, BE and LODE among midday movers
Gainers: MICT (MICT) +52%.RISE Education Cayman (REDU) +49%.Forward Industries (FORD) +29%.MOGU (MOGU) +28%.OneSmart International Education (ONE) +25%.Aduro Biotech (ADRO) +24%.Natural Gas Services (NGS) +19%.Bloom Energy (BE) +19%.Invacare (IVC) +15%.Tarena International (TEDU) +14%.Losers: Seanergy
Seekingalpha · 08/18 16:47
Healthcare - Top 5 Gainers / Losers
Gainers: Aduro Biotech (ADRO) +20%. Otonomy (OTIC) +14%. BeyondSpring (BYSI) +13%. Verrica Pharmaceuticals (VRCA) +13%. STRATA Skin Sciences (SSKN) +11%.Losers: Poseida Therapeutics (PSTX) -30%. Acer Therapeutics (ACER) -20%. Biofrontera (BFRA) -15%. Unity Biotechnology
Seekingalpha · 08/18 15:02
Chinook Therapeutics Announces $106M Private Placement Financing To Advance Precision Medicines For Kidney Disease
Benzinga · 08/18 12:19
Aduro Biotech EPS misses by $0.02, beats on revenue
Aduro Biotech (NASDAQ:ADRO): Q2 GAAP EPS of -$0.21 misses by $0.02. Revenue of $5.57M (+13.9% Y/Y) beats by $2.11M. Shares +1.4%. Press Release
seekingalpha · 08/04 01:42
Aduro Biotech (ADRO) Reports Q2 Loss, Tops Revenue Estimates
Aduro Biotech (ADRO) delivered earnings and revenue surprises of -10.53% and 76.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/03 23:15
Aduro Biotech Q2 EPS $(0.21) Up From $(0.23) YoY, Sales $5.57M Up From $4.89M YoY
Aduro Biotech (NASDAQ:ADRO) reported quarterly losses of $(0.21) per share. This is a 8.7 percent increase over losses of $(0.23) per share from the same period last year. The company reported $5.57 million in sales
Benzinga · 08/03 20:26
Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results
BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the A Proliferation Inducing Ligand (APRIL) and Stimulator of Interferon Genes (STING)
GlobeNewswire · 08/03 20:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADRO stock price target is 3.750 with a high estimate of 3.750 and a low estimate of 3.750.
EPS
Institutional Holdings
Institutions: 142
Institutional Holdings: 42.04M
% Owned: 51.80%
Shares Outstanding: 81.17M
TypeInstitutionsShares
Increased
28
2.56M
New
38
361.00K
Decreased
20
1.36M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.39%
Pharmaceuticals & Medical Research
-2.13%
Key Executives
Chairman/President/Chief Executive Officer/Director
Stephen Isaacs
Chief Financial Officer
William Kachioff
Senior Vice President/General Counsel/Secretary
Celeste Ferber
Chief Administrative Officer
Blaine Templeman
Other
Dimitry Nuyten
Lead Director/Independent Director
Stephanie O'Brien
Independent Director
William Greenman
Independent Director
Ross Haghighat
Independent Director
Frank Karbe
Independent Director
David Mack
Independent Director
Stephen Sherwin
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average ADRO stock price target is 3.750 with a high estimate of 3.750 and a low estimate of 3.750.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ADRO
Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aduro BioTech Inc stock information, including NASDAQ:ADRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADRO stock methods without spending real money on the virtual paper trading platform.